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(57) ABSTRACT 
Kay den, 
An optical coagulation monitor and the method of monitoring 
blood coagulation status are disclosed. The method includes 
positioning a sample probe containing an optical fiber within 
a circulating blood; transmitting a low-coherence light 
through the optical fiber into the blood; detecting dynamic 
light scatter signals generated by the blood within a coher-
ence volume and received through the optical fiber; analyzing 
the dynamic light scatter signals in comparison to a predeter-
mined coagulation criterion; and reporting the coagulation 
status of the blood. The method can be used for monitoring 
blood coagulation status in vivo or in vitro in real time. 
Further disclosed is a method of determining blood clotting 
time in vitro using the optical coagulation monitor. 
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OPTICAL COAGULATION MONITOR AND 
METHOD OF USE 
FIELD OF THE INVENTION 
2 
and control the therapeutic treatment. Moreover, it is also 
desirable to effectively monitor coagulation activities in vitro, 
and provide improved detection method for determining clot-
ting time. 
SUMMARY OF THE INVENTION 
In one aspect, the present invention is directed to an optical 
coagulation monitor, which comprises a sample chamber 
The present invention relates to optical coagulation moni-
tors based on low-coherence dynamic light scattering mea-
surement for determining or monitoring blood coagulation 
status in vivo or in vitro in real time and for measurement of 
blood clotting time in vitro. 
BACKGROUND OF THE INVENTION 
Blood clotting is a complex process involving multiple 
initiators and cascades of activators which ultimately lead to 
the formation of fibrin and eventually to insoluble fibrin clots. 
The blood clotting process is an indicator of serious patho-
logical conditions including thrombosis, pulmonary embo-
lism, heart attack, stroke, and coronary artery disease which is 
the primary cause of mortality in the United States. 
10 including an inlet and an outlet connected to a circulation 
path; a light source providing a low-coherence light; a sample 
probe disposed within the sample chamber, the sample probe 
comprising an optical fiber optically connected to the light 
source for transmitting the low-coherence light into a blood 
15 sample contained in the sample chamber; an optical detector 
connected to the sample probe for detecting light signals 
received from the sample probe; and a dynamic light signal 
analyzer connected to the optical detector. The optical fiber 
can be a single-mode optical fiber or a multi-mode optical 
20 fiber. 
Conventionally, blood clotting process is assessed by mea-
suring the time taken for a sample of blood to clot naturally or 
after a specific chemical coagulation initiator is introduced. 
The most commonly used tests for measuring the blood clot-
ting time are the activated partial thromboplastin time ( aPTT) 25 
test and prothrombin time (PT) test. The former is initiated by 
kaolin, PL (an emulsion of negatively charged phospholip-
ids ), and calcium; and the latter is initiated by thromboplastin 
and calcium. The conventional methods for determining the 
time of clot formations are typically based on mechanical, 30 
acoustical or electrical technologies. These methods are rela-
tively slow and the instruments involved can be relatively 
bulky. 
Optical measurements have been used in determining 
blood clotting time in vitro. U.S. Pat. No. 4,777,141 (to Calzi 35 
et al) discloses an instrument for measuring coagulation 
parameters, in which plasma and a reagent is mixed and a 
light scatter measurement is made on the mixture. The light 
scatter measurement is based on the transition of an initial 
homogenous liquid phase to a heterogeneous light-solid 40 
phase in which the threads of insoluble fibrin are formed. 
U.S. Pat. No. 5,039,617 (McDonald et al) discloses a cap-
illary flow device and the method for measuring activated 
partial thromoplastin time. This method performs an APTT 
analysis on a whole blood sample to which no anticoagulant 45 
has been added, by applying the sample to a capillary track, 
and by detecting the cessation of blood flow as determined by 
a light scatter measurement on blood cells passing through a 
specific location of the track. 
On the other hand, U.S. Pat. No. 6,958,816 (to Dogariu et 50 
al) discloses methods and systems that use dynamic light 
scattering, for investigating local rheological responses of 
complex fluids over a frequency range larger than that pro-
vided by standard instrumentation. 
Currently, no instrument is available for monitoring blood 55 
coagulation status in vivo in real time. It is known that patients 
who have undergone major surgery are at great risk of throm-
bosis up to 72 hrs after surgery. Under these conditions any 
significant increase in blood viscosity may most probably 
indicate the onset of thrombosis. 60 
Therefore, there is a strong need for instrumentations and 
methodologies that enable early detection of clotting activa-
tion in real time, so that early therapeutic intervention can be 
started timely to avert thrombosis and death. Furthermore, 
there is further a strong need in the ability of monitoring the 65 
effectiveness of procoagulant or anticoagulant therapies in 
real time, which would allow the physicians to understand 
In a further aspect, the present invention is directed to a 
method of determining or monitoring blood coagulation sta-
tus. In one embodiment, the method comprises positioning a 
sample probe comprising an optical fiber within a circulating 
blood; transmitting a low-coherence light through the optical 
fiber into the blood; detecting dynamic light scatter signals 
generated by the blood within a coherence volume and 
received through the optical fiber; analyzing the dynamic 
light scatter signals in comparison to a predetermined coagu-
lation criterion; and reporting a coagulation status of the 
blood. The monitoring blood coagulation status is in real 
time, and the circulating blood can be either in vivo or in vitro. 
In one embodiment, analyzing the dynamic light scatter 
signals of the blood cells generates a power spectrum of 
intensity vs. frequency. The predetermined coagulation crite-
rion can be a predetermined value or a range of one or more 
parameters obtained from the power spectrum; a shape or a 
rate of change in the shape of the power spectrum; a prede-
termined amount of change of storage modulus G', loss 
modulus G", or loss tangent tano. In another embodiment, 
analyzing the dynamic light scatter signals of the blood cells 
generates temporal autocorrelation of the dynamic light scat-
ter signals. The predetermined coagulation criterion can be a 
predetermined value or a range of one or more parameters 
obtained from the temporal autocorrelation, or a predeter-
mined amount of change in the shape of the temporal auto-
correlation, or in the width of the temporal autocorrelation. 
In a further aspect, the present invention is directed to a 
method of determining blood clotting time in vitro. In one 
embodiment, the method comprises mixing a coagulation 
initiator with a blood sample to form a sample mixture; trans-
mitting a low-coherence light into the sample mixture; detect-
ing dynamic light scatter signals generated by the sample 
mixture within a coherence volume; analyzing the light sig-
nals in comparison to a predetermined clotting criterion; and 
reporting the blood clotting time of the blood sample. The 
sample mixture is in a flowing or static condition during the 
detection. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic illustration of the optical coagulation 
monitor of one embodiment of the present invention. 
FIG. 2 illustrates a portion of a multi-mode optical coagu-
lation monitor in one embodiment of the present invention. 
FIG. 3 shows the power spectra of a whole blood sample 
obtained using the optical coagulation monitors with a single-
US 7,821,620 B2 
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mode optical fiber and a multi-mode optical fiber, as 
described in Examples 1 and 2, respectively. 
FIG. 4 shows the power spectra of the reconstructed whole 
blood samples with different levels of hematocrit, as 
described in Example 3. 
FIG. 5 shows the power spectra of a blood sample obtained 
at different time after addition of thrombin, as described in 
Example 4. 
4 
used to control the circulating blood at about 37° C. Other 
suitable temperature control device can also be used for the 
purpose of the present invention, for example, a semiconduc-
tor peltier. 
Sample probe 20 comprises an optical fiber 80 which is 
also referred to as the sample branch of the optical detection 
system. Optical fiber 80 connects to fiber optic splitter 100 at 
its one end 84 and the opposing end 82, which is referred to as 
the sampling end hereinafter, is disposed within sample FIG. 6 shows the power spectra of a blood sample obtained 
at different time after addition of thrombin, as described in 
Example 5. 
FIG. 7 is a log-log representation of FIG. 6, showing the 
changes in the slope of the power spectra, as described in 
Example 5. 
10 chamber210 and immersed within the whole blood sample to 
be measured. Optical fiber 80 can be either a single-mode or 
a multi-mode optical fiber, as described in more detail below. 
In one exemplary embodiment, sample probe 20 includes a 
needle 22 with optical fiber 80 embedded within the needle, 
FIG. 8 shows the power spectra of washed red blood cells 
suspended in PBS and in PBS solutions containing different 
concentrations offibrinogen, as described in Example 6. 
15 and with sampling end 82 of optical fiber 80 disposed at the 
end of needle 22 and exposing to the blood. 
The light source 50 provides a low-coherence light. Pref-
erably, the low-coherence light has a coherence length from 
about 5 µm to about 50 µm, and more preferably, from 8 µm 
FIG. 9 shows the power spectra of washed red blood cells 
suspended in PBS and after addition of albumin in the PBS, as 
described in Example 6. 
DETAILED DESCRIPTION OF THE INVENTION 
20 to about 20 µm. Suitable low-coherence light source includes, 
but is not limited to, superluminescent diode (SLD), a mul-
tiple quantum well light emitting diode (MQWLED), a mod-
elocked Ti:Al2 0 3 laser, a laser pumped fluorescent organic In one aspect, the present invention provides optical coagu-
lation monitors for monitoring blood coagulation status in 25 
vivo or in vitro, or for measurement of blood clotting time in 
vitro. 
dye, and a superfluorescent optical fiber. 
In an exemplary embodiment as illustrated in Example 1, a 
superluminescent diode (SLD) is used as the light source. In 
FIG. 1, the component 40 is a SLD current and temperature 
controller for the SLD light source. 
In one embodiment, the optical coagulation monitor com-
prises a sample chamber connected to a circulation path, a 
low-coherence light source, a sample probe comprising opti-
cal fiber, an optical detector, and a dynamic light signal ana-
lyzer. FIG. 1 illustrates a schematic diagram of the optical 
coagulation monitor in one embodiment of the present inven-
tion. Herein, the term of dynamic light signal analyzer refers 
to a light signal analyzer that enables analysis of dynamic 
light signals. The term of dynamic light signals refers to 
time-dependent fluctuations observed when light is scattered 
30 
The low-coherence light generated by light source 50 is 
transmitted by optical isolator 60 to sample probe 20. In one 
embodiment, optical isolator 60 is a fiber based. A fiber optic 
splitter lOOa or a fiber optic coupler lOOb connects to optical 
isolator 60 and optical detector 70 at one side and to optical 
35 
fiber 80 of sample probe 20 at the other side. The fiber optic 
splitter or coupler directs the low-coherence light from light 
source 50 into optical fiber 80 of sample probe 20, and at the 
same time directs the light signals received from the sampling 
end 82 of optical fiber 80 to optical detector 70. 
by moving scattering centers such that the distance between 
them is constantly changing in time. Because of the construc-
tive and destructive interferences in the scattered light, its 40 
intensity fluctuates in time and carries information about the 
movement of the scattering centers. This fluctuating intensity 
can be analyzed in either time or frequency domain. 
Optical detector 70 detects the light signals received from 
optical fiber 80 of sample probe 20. The light signals are 
converted by detector 70 to electrical signals, which are fed 
into a two-channel dynamic light signal analyzer 110. The 
two-channel dynamic light signal analyzer 110 can typically More specifically, the optical coagulation monitor shown 
in FIG. 1 includes two major segments. The first segment 
includes the low-coherence light source and dynamic light 
scatter detection components, and the second segment 
includes a blood circulation system for conditioning blood 
sample for coagulation measurement in vitro. 
45 operate in the Fast Fourier Transform (FFT) mode with a base 
Frequency of 100 Hz and 800 FFT lines. The data generated 
by dynamic light signal analyzer 110 can be input to, through 
a general protocol interface board (GPIB) controller, and 
further processed by a personal computer 120. 
Referring to FIG. 1, the blood circulation system 200 50 
includes a sample chamber 210, which has an inlet 212 and an 
outlet 214, connected to a circulation path 220. In one exem-
plary embodiment, circulation path 220 is formed by a sili-
cone tubing with its two opposing ends connected to inlet 212 
and outlet 214. A pump 230 is connected to circulation path 55 
220 for circulating the blood within circulation path 220. 
Typically, the blood to be measured is circulated at a low flow 
rate, for example, from about 0.05 to about 1.5 ml per minute. 
The interior surface of the circulation path is compatible to 
whole blood samples, which does not induce, or is resistant 60 
to, protein precipitation. Sample chamber 210 can further 
include a reagent inlet (not shown) for introducing a coagu-
lation initiator. 
Preferably, the temperature of the blood within the circu-
lation path is controlled at about physiological temperature 65 
by a temperature control device (not shown). In one exem-
plary embodiment shown in Example 1, a water bath 250 is 
In one embodiment, the optical coagulation monitor uti-
lizes a single-mode optical fiber, which is also referred to as a 
single-mode optical coagulation monitor. Herein, the term 
"single-mode" optical fiber refers to an optical fiber having a 
narrow core diameter that only permits transmission of sub-
stantially one mode light signal. The term "multi-mode" opti-
cal fiber refers to an optical fiber having a broader core diam-
eter that permits transmission of multiple modes of light 
signals. It is noted that the term "optical fiber" used herein 
includes gradient index and step index fibers, and specialty 
fibers such as photonic crystal fiber and structured fibers, etc. 
In the single-mode optical coagulation monitor, both opti-
cal isolator 60 and optical fiber 80 of sample probe 20 are a 
single-mode optical fiber, and a fiber optic splitter lOOa is 
used. For the low-coherence light used for the purpose of the 
present invention, the single-mode optical fiber can have a 
fiber core diameter from about 6 µm to about 8 µm. In one 
exemplary embodiment, a single-mode optical fiber having a 
US 7,821,620 B2 
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wavelength of 630 run, a fiber inner jacket of 125 µm, and a 
fiber core thickness of 8 µm is used. The terminators can be 
FC/PC. 
In a further embodiment, the optical coagulation monitor 
utilizes a multi-mode optical fiber, which is referred to as a 
multi-mode optical coagulation monitor. Because the refer-
ence optical path is generated by reflection at the end of the 
fiber used to generate the measuring signal also, this interfer-
ometer is also referred to as multi-mode common path inter-
10 
ferometer. In the multi-mode optical coagulation monitor, 
two figurations can be used. In one configuration, both optical 
isolator and optical fiber of sample probe are a multi-mode 
optical fiber, and a fiber optic coupler llOb is used 
6 
The method of using the instant optical coagulation moni-
tors described above for coagulation measurement in vitro or 
monitoring blood coagulation status in vivo or in vitro are 
described hereinafter. 
It should be understood that the instant method is based on 
measurement of the mechanical fluctuations of blood cells in 
whole blood. When irradiated, the blood cells scatter light in 
a random manner as determined by their mechanical move-
ments. When the blood clotting progresses, the blood cell 
movement is affected and their limited displacement is 
detected via modifications in the fluctuations of the scattered 
light. The information regarding the clotting process, either 
being induced in vitro or naturally occurring in vivo such as 
thrombosis, is then inferred from the temporal autocorrela-
In an alternative configuration as illustrated in FIG. 2, in 
the multi-mode optical coagulation monitor 300 a single-
mode optical fiber 60a is connected to light source 50 at one 
end, and the other end is coupled to a multi-mode optical fiber 
360 by a coupler 330. Multi-mode optical fiber 360 is in tum 
connected to fiber optic coupler lOOb. For the low-coherence 
light used for the purpose of the present invention, the multi-
mode optical fiber can have a fiber core diameter from about 
15 tion of the light fluctuations or from the power spectrum, as 
described more fully hereinafter. 
Since in blood the number of red blood cells is approxi-
mately two orders higher than the number of white blood 
cells, the dynamic light scatter signals of the blood cells are 
40 µm to about 50 µm. In one exemplary embodiment, multi-
mode optical fiber 60b and 380 have a wavelength of 630 run, 
a fiber inner jacket of 125 µm thick, and a fiber core thickness 
of50 µm. The single-mode optical fiber 60a coupled to multi-
mode optical fiber 360 has a wavelength of 630 run, a fiber 
inner jacket of 125 µm thick, and a fiber core thickness of 8 
µm. 
20 predominantly from the red blood cells. Other components in 
the blood, such as proteins in the plasma can also contribute to 
the dynamic light signals, however, to a substantially lower 
extent. Therefore, the signals from the red blood cells are the 
dominant components of the dynamic light scatter signals. It 
25 is noted that the detected light signals further include the 
reflected light signals at the interface between the sampling 
end of the optical fiber and the blood. 
For the purpose of monitoring blood coagulation status or 
measurement of blood clotting time, it has been found that a 
As can be further appreciated from the schematic illustra-
tion of FIG. 2, for monitoring coagulation status in vivo, 
sample probe 320 can be directly placed into a patient's blood 
circulation, such as alongside a central line (vein or artery). 
Therefore, the term "circulating blood" used herein includes 
naturally circulating blood in vivo, and a blood circulation 
generated in vitro, such as a blood sample contained in the 
blood circulation system 200 of FIG. 1. 
30 low-coherence light having a frequency range from 600 run to 
700 run can be used. Preferably, the coherence length is from 
about 5 µm to about 20 µm, more preferably, from about 8 µm 
to about 15 µm. The coherence volume is a volume of the 
blood immediately adjacent to the sampling end of the optical 
Examples 1 and 2 illustrate specific examples of a single-
mode optical coagulation monitor and a multi-mode optical 
coagulation monitor, respectively. 
35 fiber, defined by the coherence length multiplied by the area 
of the fiber core. For example, when a multi-mode optical 
fiber having a fiber core diameter of 45 µm is used, with a 
coherence length of about 10 µm, about 15 fl of the blood 
sample is measured. Preferably, a multi-mode optical fiber is 
40 used to achieve higher detection sensitivity and higher signal-
The principle and mechanism utilizing low-coherence 
dynamic light scattering and a single-mode optical fiber for 
analyzing mechanical properties of a small volume of liquid 45 
has been fully described in U.S. Pat. No. 6,958,816, which is 
hereby incorporated by reference in its entirety. Furthermore, 
the principle and mechanism utilizing low-coherence 
dynamic light scattering and a multi-mode, common-path 
interferometry for analyzing mechanical properties of a small 50 
volume of liquid has been fully described in patent applica-
tion Ser. No. 11/399,632, which is hereby incorporated by 
reference in its entirety. 
A whole blood sample is measured using the devices 
described in Examples 1 and 2, respectively. FIG. 3 shows the 55 
obtained power spectra. As shown, the power spectrum (in-
tensity vs. frequency) obtained using the multi-mode optical 
fiber (curve B) has substantially higher intensity than the 
power spectrum obtained using the single-mode optical fiber 
(curve A). Additionally, different from the single-mode opti- 60 
cal fiber, the power spectrum obtained using the multi-mode 
optical fiber does not flatten, which indicates that the multi-
mode signal is not impacted by the noise floor, as is with the 
single-mode signal. Therefore, substantial improvements of 
signal amplitude and signal-to-noise ratio have been achieved 65 
in measuring whole blood samples using the multi-mode 
optical fiber in comparison to the single-mode optical fiber. 
to-noise ratio. 
In one embodiment, the blood clotting time is measured in 
vitro using the instant optical coagulation monitor. The 
method entails the following steps: mixing a coagulation 
initiator with a blood sample to form a sample mixture; trans-
mitting a low-coherence light into the sample mixture; detect-
ing dynamic light scatter signals generated by blood cells of 
the sample mixture within a coherence volume; analyzing the 
dynamic light signals in comparison to a predetermined clot-
ting criterion; and reporting the blood clotting time of the 
blood sample. 
Various coagulation initiators known in the art can be used 
for the purpose of the present invention. Suitable examples 
include, but are not limited to, elite, kaoline, glass cocktail, 
silica or phospholipids. Furthermore, the blood clotting time 
can also be measured without introducing coagulation initia-
tor, i.e., natural clotting of the blood in vitro. 
As described above, when the blood clotting progresses, 
the blood cell movement is affected and their limited dis-
placement is detected via modifications in the fluctuations of 
the scattered light. The dynamic light scatter signals are pre-
dominantly from the red blood cells. 
It is known, the shear stress a in a flowing fluid represents 
the force exerted by the fluid per unit surface area of a plane 
parallel to the direction of flow and is given by 
(1) 
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wherein ri is the shear viscosity and y is the shear rate. The 
shear stress a(t) introduced by a small-amplitude deforma-
tion is sinusoidal and is defined as 
a(t)~y0[G'( w )sin( wt)+G"( w )cos( wt)] (2) 
8 
x'(w)=~P[x"(<f)a.; 2d<f, 
7r '::i -w 
(9) 
a regime known as the linear viscosity regime, where w is the 
angular frequency. The coefficient of the first term, G'( w ), in 
phase with the strain, is know as the storage modulus, and 
G"(w), corresponding to the term in phase with the rate of 10 
strain, is known as the loss modulus. The former represents 
the storage of elastic energy by the fluid, the latter represents 
viscous dissipation. The ratio, known as the loss tangent, is 
defined as 
Thus, both G' and G" can be extracted from the measured 
power spectrum of the blood sample. 
As illustrated in FIG. 3, the obtained power spectrum is a 
two dimensional curve of intensity vs. frequency. Based on 
one or more of the spectral features, such as shape, slope, 
shear modulus G( w) including the storage modulus G'( w) and 
the loss modulus G"(w), and other derived parameters, the 
predetermined clotting criterion can be determined using a 
G"/G'o=tanli 
15 known blood clotting time of a reference. In one example, the 
(3) 
rate of change in the slope of a power spectrum is used as the 
and is a measure of the fluidity of the material; i.e., tan 11>> 1 
for liquid-like materials, while the opposite holds for solid-
like materials. The storage and loss moduli collectively are a 20 
complex function G*, known as complex shear modulus, 
predetermined clotting criterion. In another example, the 
storage modulus G'( w ), the loss modulus G"( w ), or the com-
bination thereof is used as the predetermined clotting crite-
non. 
It should be understood that all parameters described 
above, the power spectrum, G', G", and tano, have a depen-
dence on frequency w. Therefore, the predetermined clotting 
criterion can be established in terms of the absolute value of 
one or more parameters in a narrow frequency range or via a 
global estimation over the entire spectral range available to 
G*=G'+iG" (4) 
Wherein i=(-1 )112 . The complex viscosity is then defined as 
The frequency-dependence of the storage and shear moduli 
provides information to the structure of complex materials. 
For liquid-like materials, one has 
G'<<G" (5) 
and G' is proportional to w2 ; G" is proportional to w, whereas 
for solid-like materials both are independent of frequency, but 
G'>>G". 
In one embodiment of the present invention, the measur-
able quantity is a power spectrum of the scattered light fluc-
tuations P(w). It has been found that in the high-frequency 
region, P( w) is directly related to the power spectral density of 
the particle displacements (llr2 ( w) ): 
(6) 
The high-frequency dependence of the shear modulus G(w) 





wherein a is the radius of the light scattering particles, and 
xC w) comprises two parts, the storage response x'C w) and loss 
response x"(w) that characterizes the fluid through 
w 
x"(w) = 2ksT -(Ll.r2(w)), 
(8) 
and the storage x'(w) and loss response x"(w) are related 
through the Kramers-Kronig relationship: 
25 
the measurement. 
It is further noted that the power spectrum is a result of 
30 
measurement of the dynamic light scatter signals in fre-
quency domain. Alternatively, the dynamic light scatter sig-
nals can also be measured in time domain. In other words, 
instead of analyzing the power spectrum one, can perform the 
entire analysis in the "time domain". More specifically, in the 
35 
time domain measurement the dynamic light scatter signals 
from the detector are not fed into a power spectrum analyzer, 
instead, one evaluates the autocorrelation of the time series 
representing the detector output. This temporal autocorrela-
tion has a simple Fourier transform relationship with the 
40 
power spectrum. It should be understood that the information 
revealed from either the power spectrum or temporal auto-
correlation is the same. 
As such, in a further embodiment, the dynamic light scatter 
signals of a blood sample are recorded and the temporal 
45 autocorrelation is determined. The predetermined clotting 
criterion can be a predetermined value or a range of one or 
more parameters obtained from the temporal autocorrelation, 
such as one or more parameters defining the shape of the 
autocorrelation function from a reference, or a predetermined 
50 amount of change in the shape or width of the time autocor-
relation. 
It should be understood that for measuring blood clotting 
time in vitro, not only the sample probe 20 or 120 comprising 
an optical fiber as described above can be used for the mea-
55 surement, an open system as those illustrated in FIGS. 10 and 
11 ofU.S. Pat. No. 6,958,816 can also be used. Furthermore, 
in this embodiment the sample mixture can be either in a 
circulating or a static condition. In the latter case, the sample 
mixture can also be simply placed in a sample well, allowing 
60 placement of the sampling end of the optical fiber within the 
well or configured to receive the incident light from the open 
system. 
The red blood cell concentration in the normal peripheral 
blood is from about 4.2 to 5.9xl 012 cells per liter. Hematocrit 
65 (Hct) is defined as the proportion of blood volume that is 
occupied by red blood cells. The normal hematocrit range for 
male is from about 45% to about 52%, and for female is from 
US 7,821,620 B2 
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about 37% to about 48%. As described above, the dynamic 
light scatter signals are predominantly from the red blood 
cells, the dependency of the dynamic light scatter signals on 
the red blood cell concentration of a sample has been 
assessed. 
10 
As shown in Example 3, the sensitivity of the power spec-
trum to the hematocrit (Hct) level was measured using the 
multi-mode optical coagulation monitor described in 
Example 2. Reconstructed anti-coagulated whole blood 
samples with different hematocrit were used for the measure- 10 
ment. More specifically, a series of whole blood samples with 
increasing amounts of red blood cells from plasma only, Hct 
Example 5 further illustrates a specific method using the 
change in the shape of the power spectra with time for mea-
surement of blood clotting time of whole blood samples. As 
shown, after introducing thrombin into a whole blood sample, 
blood coagulation occurred within about 5 to 7 minutes, and 
an increase in viscosity was observed over time as illustrated 
in FIG. 6. Sequential increases of the blood viscosity were 
observed to the point of gel formation due to clotting. 
FIG. 6 shows an expanded region of the collected power 
spectra, and a significant decrease in the bandwidth is 
observed. It has been found that the actual changes in the 
viscosity properties are best demonstrated by the changes in 
the shape of the power spectra. FIG. 7 is a log-log represen-
tation of the power spectra shown in FIG. 6. As can be readily 
of 30%, 35%, 40%, 45%, and 50% are measured. Among 
these reconstructed whole blood samples, the samples having 
Hct of 40%, 45%, and 50% are within the clinical normal 15 appreciated from FIG. 7, the slope of the power spectrum 
changes significantly as the aggregation process evolves. range. 
FIG. 4 displays the obtained power spectra, which shows 
the dependency of the power spectrum on the hematocrit of 
the whole blood samples in the hematocrit range tested. How-
ever, within the clinical normal hematocrit range, the power 
spectra are essentially independent of the hematocrit of the 
blood samples. 
Table 1 shows the parameter a obtained by linear fitting of 
the power spectrum measured at high frequencies, which is 
indicative of the type of diffusion regime. A strong depen-
dence of a on the hematocrit has been observed. This obser-
vation indicates a tendency towards normal diffusion (a=l), 
when the hematocrit increases. Since the intensity of the 
signal obtained for plasma only is much lower than the inten-
sity of the sample having 40% Hct, it can be concluded that 
for the whole blood samples having hematocrit within the 
clinical normal range, the heterodyne signal is mainly due to 
the motion of the red blood cells. 
Example 4 illustrates the measurement of dynamic viscos-
ity change during thrombosis of a whole blood sample using 
the multi-mode optical coagulation monitor described in 
Example 2. As shown, after introducing thrombin into the 
whole blood sample, coagulation occurred as indicated by the 
change of the power spectrum with time due to increase in 
viscosity. After 22 minutes, a clot formed in front of the 
optical fiber, and no further change was noted in the spectrum 
afterwards. FIG. 5 shows the obtained power spectra of the 
blood sample at 7, 15 and 22 minutes. Moreover, FIG. 5 
further shows the power spectrum of washed red blood cells 
suspended in PBS, which represents the minimum viscosity 
obtainable using erythrocytes suspended in a medium with a 
viscosity close to water. 
The results show that the instant optical coagulation moni-
tor can detect both reduction and increase in viscosity of the 
blood samples. In the case of increased viscosity due to blood 
coagulation, sequential increases are observed to the point of 
gel formation due to clotting. 
Quantitative determination of the viscoelastic properties can 
be made based on these changes of the spectra. It is noted that 
when the change in the slope of the spectrum is used as the 
20 parameter for determining the blood clotting time, the mea-
surement is independent of the absolute value of the initial 
viscosity of a blood sample. This result illustrates that the 
optical coagulation monitor and the method of the present 
invention can be used for a quantitative measurement ofblood 
25 clotting time. 
It is known that the two major proteins in blood are albumin 
(normal range 60-80 mg/ml) and fibrinogen (normally about 
3 mg/ml). Albumin is primarily responsible for the viscosity 
of blood, and it is important in regulating osmotic pressure 
30 and water retention in the circulation. Fibrinogen concentra-
tion gradually increases with age to concentrations of 6 
mg/ml or more in both males and females, therefore, it is a 
risk factor for cardiovascular disease. 
The sensitivity of the instant optical coagulation monitor to 
35 the difference in fibrinogen and albumin concentrations, and 
the viscosity change affected by the proteins has also been 
assessed. Example 6 illustrates two specific examples. 
In the first example, washed red blood cells were sus-
pended in PBS with a hematocrit of 45%, and in PBS solu-
40 tions that contained 1.3 and 5.5 mg/ml offibrinogen, respec-
tively. As described above, the washed red blood cells 
suspended in PBS alone represent the minimum viscosity 
detectable using erythrocytes as the viscosity reporters, since 
the viscosity of PBS is close to that of water, and significantly 
45 less than that of plasma. The power spectra of these three 
suspensions were obtained using the multi-mode optical 
coagulation monitor described in Example 2. As shown, the 
viscosity increased with the concentration of fibrinogen. 
Moreover, the increase in viscosity observed at a fibrinogen 
50 concentration of 1.3 mg/ml indicated that the multi-mode 
optical coagulation monitor of the present invention was suf-
ficiently sensitive to detect small changes in fibrinogen con-
centration. This result demonstrates that the process of blood clotting 
can be dynamically tracked over a period of time by measure-
ment of increasing viscosity. This is particularly relevant in 55 
the context of early detection of onset of thrombosis in clini-
In the second example, the washed red blood cells were 
suspended in PBS with a hematocrit of 45%. Albumin was 
added into the circulation of the red blood cell suspension and 
the power spectra were recorded after the addition of the 
protein. FIG. 9 shows the obtained power spectra of blood 
cells in PBS, and with addition of 500 µl and 1000 µl of 
cal settings such as in intensive care units. Patients who have 
undergone major surgery are at great risk of thrombosis up to 
72 hours after surgery. Under these conditions any significant 
increase in blood viscosity may most probably indicate the 60 
onset of thrombosis. Using the instant optical coagulation 
monitor in vivo such as in the patient's circulation (possibly 
alongside a central line or canula ), as described in the further 
embodiment of the present invention hereinafter, could pro-
vide early detection of clotting activation, therefore, thera- 65 
peutic intervention could be started to avert overt thrombosis 
and death. 
albumin, respectively. As shown, addition of albumin to 
washed erythrocytes increased viscosity in a similar manner 
to fibrinogen, further indicating the ability of the instant 
monitor in detecting changes in viscosity induced by proteins. 
Since these proteins are the major components of plasma, the 
results of Example 6 have further indicated the utility of the 
instant optical coagulation monitor in monitoring of coagu-
lation status in vivo, as described more fully hereinafter. 
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In a further embodiment, the present invention provides a 
method of determining or monitoring the coagulation status 
in vivo or in vitro in real time. The method entails the follow-
ing steps: positioning a sample probe comprising an optical 
fiber within a circulating blood, transmitting a low-coherence 
light through the optical fiber into the blood, detecting 
dynamic, light scatter signals generated by the blood within a 
coherence volume and received through the optical fiber, 
analyzing the dynamic light signals in comparison to a pre-
determined coagulation criterion, and reporting a coagulation 10 
status of the blood. 
Herein, the term "coagulation status" refers to a blood 
property relating to coagulation process, such as viscosity of 
12 
As can be appreciated, since the instant method detects the 
coagulation status in vivo in real time, the patient's response 
to a drug, either increasing or reducing the risk of clotting, can 
be monitored and timely reported. As such, important infor-
mation, such as the rate of response, adverse response if any, 
and stability of coagulation condition, can be revealed using 
the instant method. This real time detection capacity has 
never been achieved previously with existing technologies. 
The instant method can also be used to evaluate risk of 
excessive bleeding prior to a surgical procedure (i.e., pre-
surgical screening), monitor bleeding disorders, and can be 
used for point-of-care testing to monitor a patient's blood 
coagulation level within therapeutic range, real-time assess-
ment of coagulophaties, or used postoperative to monitor a whole blood, or a change of a blood property relative to 
time, such as blood viscosity change before, during and after 
a surgical procedure, or relative to a treatment, such as pro-
coagulant or anticoagulant therapy. 
15 medication effects. 
As a specific example, the instant method can be used to 
monitor the effectiveness of procoagulant or anticoagulant 
therapies, and particularly to monitor the effect of therapeutic 
intervention of thrombosis, for example, monitoring a patient 
For determination of the coagulation status, the predeter-
mined coagulation criterion can be any one of those param-
eters described above that can be used as a predetermined 
clotting criterion, either in the frequency domain or the time 
domain. For example, using the shape, slope, shear modulus 
G( co) including the storage modulus G'( co) and the loss modu-
lus G"( co), or other derived parameters of a power spectrum, 
20 under the treatment of a fibrinolytic agent, such as streptoki-
nase. Using the instant optical coagulation monitor, the phy-
sician can observe the arrest of viscosity increase due to 
inhibition of clotting, as well as subsequent viscosity 
decrease as fibrin oligomers and polymer strands are broken 
or the shape or change of the shape or width of the temporal 
autocorrelation, the predetermined coagulation criterion can 
25 down to smaller, less viscous fibrin degradation products. 
The instant multi-mode optical coagulation monitor as 
illustrated in FIG. 2 and described in Example 2 is currently 
used for research purpose in a clinic for monitoring patients' 
coagulation status during surgical procedures (such as a car-
diopulmonary bypass). This, for the first time, enables in vivo 
monitoring of a patient's coagulation status in real time in a 
clinical environment. Therefore, the present invention pro-
vides a significant breakthrough in the early detection of the 
onset of thrombosis. The resultant early therapeutic interven-
be determined with a known value of the parameter from a 
reference. In one example, the predetermined coagulation 
criterion is the average value of the loss tangent obtained from 
the measurement of one or more normal subjects. In another 30 
example, the predetermined coagulation criterion is a prede-
termined amount of change in the width or the shape of the 
temporal autocorrelation obtained from the measurement of 
one or more normal subjects. 
Moreover, in terms of monitoring, the predetermined 
coagulation criterion can be one or more of the above 
described parameters at a reference point of the patient's own 
blood, for example, the average value of the loss tangent 
obtained from a patient prior to beginning a surgical proce-
40 
dure, or a clinical treatment. The predetermined coagulation 
criterion can also be an external reference, for example, a 
threshold for detection of thrombosis established based on 
35 tion can undoubtedly save lives. 
clinical statistics or reference controls. 
Furthermore, it should be understood that the predeter- 45 
mined coagulation criterion can also be established based on 
(i) "instantaneous" measurement of one or more of these 
parameters, or (ii) the time evolution of one or more of these 
parameters. "Instantaneous" measurement means one rapid 
measurement of the power spectrum (typically few seconds), 50 
while the time evolution of a parameter is followed for a 
longer period of time (for example minutes, or tens of min-
utes). The predetermined coagulation criterion can be deter-
mined with a known instantaneous value of the parameter 
from a reference or can be determined with a known time 55 
dependence of the parameter from a reference. 
The following examples are illustrative of the invention 
and are in no way to be interpreted as limiting the scope of the 
invention, as defined in the claims. 
EXAMPLE 1 
A Single-Mode Optical Coagulation Monitor 
An optical coagulation monitor as shown schematically in 
FIG. 1 was constructed. The major components are described 
below. 
Light source (50) was a superluminiscent diode (SLD) 
from SUPERLUM (Russia), which had the spectral band-
width ofFWHM 9.0 nm, centered at 676.2 nm. The spectral 
ripple of the light source was about 0.4% and photodiode 
current was around 0.954 mA. The SLD was pigtailed with 
single-mode optic fiber having a fiber inner jacket of 125 µm 
thick, a fiber core thickness of 8 µm, and FC/ APC termina-
tion. SLD current and temperature controller (40) was a 
PILOT-2 from SUPERLUM. Optical isolator (60) was a 
single-mode optical fiber with a wavelength of 630 nm from 
Optics for Research (Caldwell, N.J.). The fiber inner jacket 
was 125 µm thick, and the fiber core thickness was 8 µm. 
To function as an in vivo diagnostic indicator, one or more 
of the selected parameters can be illustrated in a manner 
convenient for the clinical practitioners to use. The predeter-
mined coagulation criterion can be expressed as a threshold or 
a defined acceptable range. If the selected parameter is below 
the threshold or within the range, it indicates a normal coagu-
lation status. Alternatively, when the selected parameter is 
above the threshold or outside the range, the report indicates 
an abnormal coagulation status. Moreover, since the magni-
tude of the parameter is quantitative, severity of the patient's 
condition can also be detected in real time. 
60 Terminators were FC/PC. 
The sample probe (20) comprised a needle (22) with a 
single-mode optical fiber (80) disposed within. The needle 
was a 23 gauge (one inch length) Precisionglide from BD 
(Franklin Lakes, N.J.). A single-mode optical fiber from 
65 Thorlabs (Newton, N.J.) was used, which had a wavelength of 
630 nm, a fiber inner jacket of 125 µm thick, and a fiber core 
thickness of 8 µm. The terminators were FC/PC. 
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each sample, and the optical fiber of the sample probe was 
cleaned after measurement of each sample. The whole blood 
collected in acid citrate dextrose (ACD) was supplied by 
Valley Biomedical Products and Services, Inc. (Winchester, 
Fiber optic splitter (100) was a 2xl splitter type from 
Newport (Irvine, Calif.). The fiber type was single-mode fiber 
with a wavelength of 630 nm. Terminators were FC/PC. The 
fiber inner jacket thickness was 125 µm, and the fiber core 
thickness was 8 µm. 5 Va.). 
The optical detector (70) was a Model 2001 from New 
Focus (San Jose, Calif.) which was carefully chosen to pro-
vide low-noise detection, variable-gain transimpedance 
amplification of up to 90 dB in 10-dB steps, and two adjust-
able frequency filters. This particular design allowed select- 10 
ing the frequency region of interest before additional ampli-
fication. The high-pass filter could be adjusted to eliminate 
residual 60-Hz noise, while the independent low-pass filter 
could be set to select the bandwidth of interest therefore 
allowing for efficient and rapid measurements. 15 
A two-channel dynamic light signal analyzer (110), SR 785 
from Stanford Research Systems (Sunnyvale, Calif.) was 
used to receive and process the light signals. The analyzer was 
usually operated in the FFT mode with a base Frequency of 
100 Hz and 800 FFT lines. The data viewer, SR785 Data 20 
Viewer (Version 1.0) from Stanford Research Systems, was 
accessed via GPIB to provide further data processing by a 
personal computer (120). 
The blood circulation system (200) included a sample 
chamber (210), of which inlet 212 and outlet 214 were con- 25 
nected to two opposing ends of a silicone tubing 8060-0020 
from Nalgene (Rochester, N.Y.). A Peri-Star 500291 high 
performance digital peristaltic pump (230) from World Pre-
cision Instruments (Sarasota, Fla.) was used. The pump had a 
fluid flow range of 0.1-80 ml/min. A microprocessor con- 30 
trolled 280 Series water bath from PRECISION (Champaign, 
Ill.) was used. The temperature was controlled at about 3 7° C. 
during the measurement of blood samples. 
EXAMPLE2 
A Multi-Mode Optical Coagulation Monitor 
A multi-mode optical coagulation monitor (300), as shown 
schematically in FIG. 2, was constructed. 
A single-mode optical fiber ( 60a ), as described in Example 
35 
40 
1, was connected to the light source at one end, and was 
coupled to a multi-mode optical fiber (360) at the opposing 
end by a coupler (330). The multi-mode optical fiber (60b) 
was in tum connected to the coupler (llOb ). Both multi-mode 45 
optical fiber (60b) and sample branch (380) were a graded 
index multimode fiber from Newport (Irvine, Calif.), which 
operated at a wavelength of 630 nm and had a core thickness 
of 56 µm. The terminators were FC/PC. 
The temperature of the blood sample in the sample cham-
ber in the measurements of the samples having Hct of 30% 
and 35% was at 36.6° C., in the measurements of plasma, and 
samples having Hct of 40% and 45% was at 35.6° C., and in 
the measurements of the sample having Hct of 50% was at 37° 
C., respectively. Each sample was circulated for 5 minutes on 
the pump at a flow rate of 0.87 ml/min, before the power 
spectrum was recorded. The light source was operated at 90 
mA. 
FIG. 4 shows the obtained the power spectra, wherein each 
curve represents an average of 200 measurements of the 
power spectrum. As shown, the power spectra of the whole 
blood samples depended on the hematocrit of the whole blood 
samples within the hematocrit range tested. However, within 
the clinical normal hematocrit range, the power spectra were 
essentially independent of the hematocrit of the blood 
samples. 
Table 1 shows the parameter a obtained by linear fitting of 
the power spectrum measured at high frequencies, which was 
indicative of the type of diffusion regime. A strong depen-
dence of a on the hematocrit was observed. This observation 
indicated a tendency towards normal diffusion (a=l), when 
the hematocrit increased. Since the intensity of the signal 
obtained for plasma only was much lower than the intensity of 
the sample having a Hct of 40%, it could be concluded that for 
the whole blood samples having hematocrit within the clini-
cal normal range, the heterodyne signal was mainly due to the 
motion of the red blood cells. 
TABLE 1 









Measurement of Dynamic Viscosity Change during 
Thrombosis 
3.8 ml of an anti-coagulated whole blood sample was 
placed into the sample chamber of the multi-mode optical 
coagulation monitor described in Example 2. The whole 
All other components, including light source, SLD current 50 
and temperature controller, detector, two-channel dynamic 
light signal analyzer, personal computer, needle of the sample 
probe were the same as those described in Example 1. For in 
vitro measurement, the blood circulation system (200) 
described in Example 1 can be used. 55 blood sample had a hematocrit of 45%. The temperature of 
the blood was controlled at 35.8° C. during the measurement, 
and the flow rate of the pump was at 0.87 ml/min. The light 
source was at 90 mA. 
EXAMPLE3 
Dependence of Power Spectrum on the Hematocrit 
The sensitivity of the power spectrum to the hematocrit 
(Hct) was measured using the multi-mode optical coagulation 
monitor described in Example 2. 
A series of 4 ml reconstituted blood samples with increas-
ing amounts of red blood cells: plasma, Hct of 30%, 35%, 
40%, 45%, and 50% were used for the measurement. The 
tubing and needles were changed for the measurement of 
12 µl ofthrombin (100 U/ml) was added into the circulating 
60 blood in 3 µl increments every 10 minutes over a period of 20 
minutes. The thrombin was pre-diluted in a phosphate buffer 
saline (PBS). The power spectra were recorded after each 
injection every 30 seconds for 10 minutes, no change of the 
power spectrum was observed. Then, additional 6 µl ofthrom-
65 bin was added into the blood, and the power spectra were 
recorded every 30 seconds for 30 minutes. As shown in FIG. 
5, changes in viscosity with time were observed. After 22 
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minutes, a clot formed in front of the optical fiber, and no 
further change was noted afterwards. FIG. 5 showed the 
obtained power spectra at 7, 15 and 22 minutes. Each curve 
was averaged 200 times. FIG. 5 further showed washed red 
blood cells suspended in PBS, which represented the mini-
mum viscosity obtainable using erythrocytes suspended in a 
medium with a viscosity close to water. The results showed 
linear responses across the spectral range. 
EXAMPLES 
Measurement of Blood Clotting Time of Whole 
Blood Samples 
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silicone tubing placed after the pump and preceding the 
sample chamber. The power spectra were recorded after the 
addition of the protein. FIG. 9 showed the obtained power 
spectra of blood cells in PBS, and with addition of 500 µl and 
1000 µl of albumin, respectively. As shown, addition of albu-
min to washed erythrocytes increased viscosity in a similar 
manner to fibrinogen, again indicating the ability of the moni-
tor in detecting changes in viscosity induced by proteins. 
While the present invention has been described in detail 
10 and pictorially shown in the accompanying drawings, these 
should not be construed as limitations on the scope of the 
present invention, but rather as an exemplification of pre-
ferred embodiments thereof. It will be apparent, however, that 
various modifications and changes can be made within the 
15 spirit and the scope of this invention as described in the above 
specification and defined in the appended claims and their 
legal equivalents. 
The blood clotting time was measured using the multi-
mode optical coagulation monitor described in Example 2 
with the blood circulation system described in Example 1. 
The instrument setting described in Example 4 was used. The 
two units of whole blood were collected inACD (from Valley 
Biomedical Products and Services, Inc.), and had a hemat- 20 
ocrit of 45% and 41 %, respectively. 
What is claimed is: 
1. An optical coagulation monitor comprising: 
(a) a sample chamber including an inlet and an outlet 
connected to a circulation path; 
3 µl of thrombin per 3 ml of blood were mixed with the 
blood and directly aspirated at a pump speed of 5-1.2 ml/min 
into the blood circulation system. The power spectrum was 
recorded immediately, and every 30 seconds thereafter. Blood 25 
coagulation occurred within about 5 to 7 minutes, and an 
increase in viscosity was observed over time as illustrated in 
FIG. 6. Sequential increases of the blood viscosity were 
observed to the point of gel formation due to clotting. 
(b) a light source providing a low-coherence light; 
(c) a sample probe disposed within said sample chamber, 
said sample probe comprising an optical fiber optically 
connected to said light source for transmitting said low-
coherence light into a blood sample contained in said 
sample chamber; 
(d) an optical detector connected to said sample probe for 
detecting light signals received from said sample probe; 
FIG. 6 showed an expanded region of the collected power 30 
spectra and a significant decrease in the bandwidth was 
observed. The actual changes in the viscosity properties were 
best demonstrated by the changes in the shape of the power 
spectra. FIG. 7 was a log-log representation of the power 
spectra. As shown, the slope of the power spectrum changed 35 
significantly as the aggregation process evolved. 
( e) a dynamic light signal analyzer connected to said opti-
cal detector for analyzing said dynamic light scatter 
signals in comparison to a predetermined coagulation 
criterion; and 
(f) a viewer for reporting a coagulation status of said blood. 
2. The optical coagulation monitor of claim 1 further com-
prising a pump connected to said circulation path to circulate 
said blood sample through said sample chamber. EXAMPLE6 
Detection of the Effect of Protein Concentration on 
Blood Viscosity 
In the first test, a whole blood collected in ACD (from 
Valley Biomedical Products and Services, Inc.) was centri-
fuged, and the plasma fraction was removed and washed 
(twice to remove all plasma) with PBS. The washed red blood 
cells were suspended in PBS alone and in PBS solutions that 
contained 1.3 and 5 .5 mg/ml of fibrinogen, respectively. The 
reconstituted blood cell suspension had a hematocrit of 45%. 
The power spectra of these three suspensions were 
obtained using the multi-mode optical coagulation monitor 
described in Example 2 with the blood circulation system 
described in Example 1. The temperature was controlled at 
36° C. and the flow rate was 0.87 ml/min. The light source was 
at 90 mA. The obtained power spectra were shown in FIG. 8. 
As shown, the viscosity increased with the increase of the 
concentration of fibrinogen. Furthermore, the increase in vis-
cosity observed at a fibrinogen concentration of 1.3 mg/ml 
indicated that the instant monitor was sufficiently sensitive to 
detect small changes in fibrinogen concentration. 
In the second test, the washed red blood cells were sus-
pended in PBS with a hematocrit of 45%. The power spectra 
of the blood cell suspension were obtained using the same 
device under the same condition, except the temperature was 
at 36.5° C. 
An albumin solution was made at a concentration of 50 
mg/ml and was added slowly through an injection port of the 
3. The optical coagulation monitor of claim 1, wherein said 
40 
optical fiber comprises a single-mode optical fiber or a multi-
mode optical fiber. 
4. The optical coagulation monitor of claim 1 further com-
prising an optical coupler connecting to said optical fiber, said 
light source, and said optical detector for directing said low-
45 coherence light from said light source into said optical fiber 
and directing said light signals received from said sample 
probe to said optical detector. 
5. The optical coagulation monitor of claim 1, wherein said 
light source comprises a superluminescent diode, a multiple 
50 
quantum well light emitting diode, a modelocked Ti:Al2 0 3 
laser, a laser pumped fluorescent organic dye, or a superfluo-
rescent optical fiber. 
6. The optical coagulation monitor of claim 1, wherein said 
low-coherence light has a coherence length of about 5 µm to 
55 about 20 µm. 
60 
65 
7. A method of determining or monitoring blood coagula-
tion status comprising: 
(a) positioning a sample probe comprising an optical fiber 
within a circulating blood; 
(b) transmitting a low-coherence light through said optical 
fiber into said blood; 
( c) detecting dynamic light scatter signals generated by 
said blood within a coherence volume and received 
through said optical fiber; 
( d) analyzing said dynamic light scatter signals in compari-
son to a predetermined coagulation criterion; and 
( e) reporting a coagulation status of said blood. 
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8. The method of claim 7, wherein said low-coherence light 
has a coherence length of about 5 µm to about 20 µm. 
9. The method of claim 7, wherein said optical fiber com-
prises a single-mode optical fiber or a multi-mode optical 
fiber. 
10. The method of claim 7, wherein said detecting said 
dynamic light scatter signals generates a power spectrum of 
intensity vs. frequency. 
11. The method of claim 10, wherein said predetermined 
coagulation criterion is a predetermined value or a range of 10 
one or more parameters obtained from said power spectrum. 
12. The method of claim 11, wherein said predetermined 
coagulation criterion is a shape or a rate of change in said 
shape of said power spectrum. 
13. The method of claim 11, wherein said predetermined 15 
coagulation criterion is a predetermined amount of change of 
storage modulus G'. 
14. The method of claim 11, wherein said predetermined 
coagulation criterion is a predetermined amount of change of 
loss modulus G". 20 
15. The method of claim 11, wherein said predetermined 
coagulation criterion is a predetermined amount of change of 
loss tangent tano. 
16. The method of claim 7, wherein said detecting said 
dynamic light scatter signals of said blood cells generates 25 
temporal autocorrelation of said dynamic light scatter sig-
nals. 
17. The method of claim 16, wherein said predetermined 
coagulation criterion is a predetermined value or a range of 
one or more parameters obtained from said temporal autocor- 30 
relation. 
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18. The method of claim 17, wherein said predetermined 
coagulation criterion is a predetermined amount of change in 
the shape of said temporal autocorrelation. 
19. The method of claim 17, wherein said predetermined 
coagulation criterion is a predetermined amount of change in 
the width of said temporal autocorrelation. 
20. The method of claim 7, wherein said circulating blood 
IS Ill VIVO. 
21. The method of claim 7, wherein said circulating blood 
is in vitro. 
22. The method of claim 7, wherein said monitoring blood 
coagulation status is in real time. 
23. A method of determining blood clotting time compris-
ing: 
(a) mixing a coagulation initiator with a blood sample to 
form a sample mixture; 
(b) transmitting a low-coherence light into said sample 
mixture; 
( c) detecting dynamic light scatter signals generated by 
said sample mixture within a coherence volume; 
( d) analyzing said dynamic light scatter signals in compari-
son to a predetermined clotting criterion; and 
( e) reporting said blood clotting time of said blood sample. 
24. The method of claim 23, wherein said sample mixture 
is in a flowing or static condition during said detecting 
dynamic light scatter signals. 
25. The method of claim 23, wherein said low-coherence 
light has a coherence length of about 5 µm to about 20 µm. 
* * * * * 
